Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Area of Science:

• Virology
• Immunology
• Structural Biology

Background:

• Antibody therapeutics and vaccines are vital for managing COVID-19 severity and fatalities.
• Mutations in SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) can reduce the effectiveness of antibody defenses during transmission and zoonotic events.

Purpose of the Study:

• To map the epitope landscape of the SARS-CoV-2 spike protein.
• To structurally characterize antibody communities targeting the receptor binding domain (RBD).
• To assess the impact of viral mutations on antibody efficacy.

Main Methods:

• Formation of an international consortium for epitope mapping.
• Structural illustration of RBD-directed antibody communities.
• Pseudovirion-based neutralization assays to evaluate antibody function against mutated spike proteins.

Main Results:

• Defined seven distinct RBD-directed antibody communities with unique binding sites and competition patterns.
• Identified specific spike mutations, both individual and clustered in variants, that impact antibody neutralization.
• Demonstrated that key classes of RBD-targeted antibodies retain neutralization activity against emerging SARS-CoV-2 variants.

Conclusions:

• Established a framework for selecting effective antibody treatment cocktails.
• Provided insights into how viral variants may influence the efficacy of antibody therapies.
• Highlighted the importance of continued surveillance of viral mutations for therapeutic development.